biostudies-literatureSpratt DENCI NIH HHS370-377https://www.ebi.ac.uk/biostudies/studies/S-EPMC10949135biostudies-literatureUnknown117(2)<h4>Purpose</h4>Intermediate-risk prostate cancer is a heterogeneous disease state with diverse treatment options. The 22-gene Decipher genomic classifier (GC) retrospectively has shown to improve risk stratification in these patients. We assessed the performance of the GC in men with intermediate-risk disease enrolled in NRG Oncology/RTOG 01-26 with updated follow-up.<h4>Methods and materials</h4>After National Cancer Institute approval, biopsy slides were collected from NRG Oncology/RTOG 01-26, a randomized phase 3 trial of men with intermediate-risk prostate cancer randomized to 70.2 Gy versus 79.2 Gy of radiation therapy without androgen deprivation therapy. RNA was extracted from the highest-grade tumor foci to generate the locked 22-gene GC model. The primary endpoint for this ancillInternational journal of radiation oncology, biology, physicsGenomic Classifier Performance in Intermediate-Risk Prostate Cancer: Results From NRG Oncology/RTOG 0126 Randomized Phase 3 Trial.PMC10949135R01 CA240991R21 CA274500UG1 CA189867UG1 CA233234U24 CA196067U10 CA180868U10 CA180822U01 CA257638Robertson JMSpratt DEEfstathiou JATran PTDavicioni EMichalski JThompson DJSParliament MBDayes ISCorrea RJMBerlin ASimko JPSandler HMLiu VYTVigneault EFeng FYGore EMSouhami LKarrison TGHall WADoncals DEfalseGenomic Classifier Performance in Intermediate-Risk Prostate Cancer: Results From NRG Oncology/RTOG 0126 Randomized Phase 3 Trial.<h4>Purpose</h4>Intermediate-risk prostate cancer is a heterogeneous disease state with diverse treatment options. The 22-gene Decipher genomic classifier (GC) retrospectively has shown to improve risk stratification in these patients. We assessed the performance of the GC in men with intermediate-risk disease enrolled in NRG Oncology/RTOG 01-26 with updated follow-up.<h4>Methods and materials</h4>After National Cancer Institute approval, biopsy slides were collected from NRG Oncology/RTOG 01-26, a randomized phase 3 trial of men with intermediate-risk prostate cancer randomized to 70.2 Gy versus 79.2 Gy of radiation therapy without androgen deprivation therapy. RNA was extracted from the highest-grade tumor foci to generate the locked 22-gene GC model. The primary endpoint for this ancill2023-01-01T00:00:00Z2023 Oct2026-06-01T13:46:22.967Z2025-04-04T13:41:35.863ZS-EPMC109491353713744410.1016/j.ijrobp.2023.04.010